

Atty Dkt. No.: IRVN-005CIP  
USSN: 09/771,263

### CLAIM AMENDMENTS

1. **(Cancelled)**
2. **(Currently amended)** The composition of claim 25, comprising ~~alloactivated~~ lymphocytes from at least two ~~different humans~~ human donors different from the patient.
3. **(Currently amended)** The composition of claim 2, comprising ~~alloactivated~~ lymphocytes from at least three ~~different humans~~ human donors different from the patient.
4. **(Currently amended)** The composition of claim 3, comprising ~~alloactivated~~ lymphocytes from at least four ~~different humans~~ human donors different from the patient.
5. **(Currently amended)** The composition of claim 2, wherein lymphocytes from at least one of the humans is claim 25, further comprising lymphocytes from the patient that have been inactivated.
6. **(Currently amended)** A pharmaceutical composition suitable for administration to a human, comprising ~~alloactivated~~ stimulated lymphocytes and a tumor associated antigen in a compatible pharmaceutical excipient, wherein administration of the composition to a patient having a tumor elicits an immunological response by the patient against the tumor.
7. **(Original)** The composition of claim 6, wherein the tumor-associated antigen is expressed on a tumor cell present in the composition.
8. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with human cells *ex vivo* expressing HLA-DR antigens that are allogeneic to both HLA-DR antigens on the lymphocytes.
9. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the

Atty Dkt. No.: IRVN-005CIP  
USSN: 09/771,263

lymphocytes become sufficiently alloactivated to be effective in eliciting an anti-tumor immunological response when administered to a human.

10. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in extending life expectancy or causing progressive reduction in tumor mass when administered to a human having a tumor.
11. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IFN- $\gamma$  by the alloactivated lymphocytes is highest.
12. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IL-2 by the alloactivated lymphocytes is highest.
13. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for between about 12 hours and 5 days.
14. **(Previously Presented)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for between about 24 and 72 hours.
15. **(Currently Amended)** ~~A kit comprising components of the composition~~ A combination of reagents for making a pharmaceutical composition, comprising the stimulated lymphocytes and the tumor associated antigen of claim 6 in separate containers.
16. **(Previously Presented)** A device for treatment of a tumor in a human patient, containing the composition of claim 25.

Atty Dkt. No.: IRVN-005CIP  
UJSSN: 09/771,263

17. **(Original)** The device of claim 16, which is an injection needle.
18. **(Original)** The device of claim 16, which is suitable for positioning by ultrasound guided endoscopy.
19. **(Previously Presented)** A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 25.
20. **(Previously Presented)** A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 25.
21. **(Original)** A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.
22. **(Original)** A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.
23. **(Original)** The method of claim 19, wherein the pharmaceutical composition is administered at or around the site of a solid tumor in the patient.
24. **(Original)** The method of claim 21, wherein the pharmaceutical composition is administered at a site distal to the tumor.
25. **(Currently Amended)** A pharmaceutical composition for administration to a human patient, comprising alloactivated lymphocytes ~~from a donor who is unrelated to the patient,~~ formulated in a compatible pharmaceutical excipient, ~~formulated~~ for administration into a solid tumor or the bed of a solid tumor in a human ~~the~~ patient, wherein administration of the composition ~~into a tumor or tumor bed in a patient in this manner~~ elicits an immunological response by the patient against the tumor.

Atty Dkt. No.: IRVN-005CIP  
USSN: 09/771,263

26. **(Previously Presented)** The composition of claim 6, which is formulated for subcutaneous or intramuscular administration, wherein administration of the composition at a site distal to the tumor elicits an immunological response by the patient against the tumor.